Innate Pharma
Grand Pré
119/121 Ancien Chemin De Cassis
Marseille
France
Tel: 33-0-4-96-19-05-50
Fax: 33-04-96-19-05-55
Website: http://www.innate-pharma.com/
Email: info@innate-pharma.com
110 articles about Innate Pharma
-
Innate Pharma to Participate in Upcoming Investor Conferences - February 07, 2023
2/7/2023
Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming investor conferences.
-
Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers
1/25/2023
Innate Pharma SA announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi.
-
Sanofi and Innate Pharma expand their longtime collaboration by licensing up to three NK cells engager programs in cancer immunotherapy valued at more than $1.4 billion.
-
Developed initially to deliver cytotoxic payloads to tumors, antibody therapeutics are evolving to provide new, next-generation conjugates and treat various diseases beyond cancer.
-
Innate Pharma to Participate in Upcoming Investor Conferences - Aug 23, 2022
8/23/2022
Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming investor conferences.
-
Many of Innate Pharma’s cancer-fighting products are making clinical progress. BioSpace spoke with the company's head of product portfolio strategy and business development, Yannis Morel, Ph.D.
-
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2022
1/24/2022
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris:– IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as at January 1, 2022.
-
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021
9/23/2021
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at September 1, 2021
-
Monalizumab Data from COAST Trial Presented at ESMO Congress 2021
9/17/2021
Innate Pharma SA today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.
-
Number of Shares and Voting Rights of Innate Pharma as of July 1, 2021
7/12/2021
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (the “ Company ” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as of July 1, 2021.
-
Innate Pharma to Present Additional Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ESMO Immuno-Oncology Virtual CongressPhase 2 expansion cohort data supports ongoing Phase 3 trial
12/3/2020
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will present additional data on its lead partnered asset, monalizumab, at the ESMO Immuno-oncology Virtual Congress being held from Dec. 9-12, 2020
-
Innate Pharma Obtains €6.8M in Public Funding for Its COVID-19 Research And Development Activities
8/11/2020
Innate Pharma SA announced the Company has obtained funding of €6.8M under the PSPC-COVID call for projects to support the Company’s COVID-19 research and development activities.
-
Innate Pharma Announces the Appointment of Joyson Karakunnel, MD, MSC, FACP as Chief Medical OfficerPierre Dodion, MD retires as Chief Medical Officer
7/16/2020
Innate Pharma SA announced the appointment of Dr. Joyson Karakunnel as Executive Vice President and Chief Medical Officer.
-
BioSpace Global Roundup, April 30
4/30/2020
Biopharma companies from across the globe provide updates on their business and pipelines. -
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 19, 2020 Without the Physical Presence of Its Shareholders
4/14/2020
Innate Pharma will hold its Annual General Meeting of Shareholders on May 19, 2020 AM in its headquarters, 117 avenue de Luminy, F-13009 Marseille.
-
A summary of daily biopharma industry news. Please check out stories that are trending on March 23, 2020.
-
Innate Pharma Reports Full Year 2019 Financial Results and Business Update
3/10/2020
Innate Pharma SA reported its consolidated financial results for the year ending December 31, 2019. The consolidated financial statements are attached to this press release..
-
First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors
3/10/2020
Anti-CD39 monoclonal antibody, IPH5201, advances to first-in-human clinical trial; first molecule from Innate/AstraZeneca expanded collaboration progressing to the clinic
-
French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides
1/13/2020
Following discussions with the Company, the ANSM decision to allow new patient recruitment to resume in Sézary syndrome and MF in France is based on an assessment of the unmet medical need and the lack of currently available standard of care options.
-
Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial
1/9/2020
Innate Pharma SA announced a regulatory update regarding its TELLOMAK Phase II trial, evaluating the efficacy and safety of lacutamab in patients with advanced T-cell lymphomas.